$14.31
1.35% yesterday
Nasdaq, Dec 24, 10:10 pm CET
ISIN
US47103J1051
Symbol
JANX

Janux Therapeutics Inc Stock price

$14.31
-17.22 54.61% 1M
-9.04 38.72% 6M
-39.23 73.27% YTD
-41.83 74.51% 1Y
+2.45 20.66% 3Y
-10.84 43.10% 5Y
-10.84 43.10% 10Y
-10.84 43.10% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.19 1.35%
ISIN
US47103J1051
Symbol
JANX
Industry

Key metrics

Basic
Market capitalization
$849.3m
Enterprise Value
$-139.7m
Net debt
positive
Cash
$989.0m
Shares outstanding
60.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
84.9 | 91.9
EV/Sales
negative | negative
EV/FCF
2.0
P/B
0.9
Financial Health
Equity Ratio
96.3%
Return on Equity
-6.7%
ROCE
-14.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$10.0m | $9.2m
EBITDA
$-142.2m | $-162.7m
EBIT
$-144.3m | $-166.5m
Net Income
$-101.9m | $-123.7m
Free Cash Flow
$-71.4m
Growth (TTM | estimate)
Revenue
-23.4% | -12.8%
EBITDA
-69.6% | -68.1%
EBIT
-67.9% | -68.4%
Net Income
-68.3% | -79.3%
Free Cash Flow
-88.8%
Margin (TTM | estimate)
Gross
-
EBITDA
-1,422.2% | -1,760.6%
EBIT
-1,442.9%
Net
-1,019.0% | -1,338.6%
Free Cash Flow
-714.0%
More
EPS
$-1.6
FCF per Share
$-1.2
Short interest
18.2%
Employees
103
Rev per Employee
$100.0k
Show more

Is Janux Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Janux Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Janux Therapeutics Inc forecast:

24x Buy
92%
2x Hold
8%

Analyst Opinions

26 Analysts have issued a Janux Therapeutics Inc forecast:

Buy
92%
Hold
8%

Financial data from Janux Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
10 10
23% 23%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 39 39
0% 0%
391%
- Research and Development Expense 115 115
92% 92%
1,152%
-142 -142
70% 70%
-1,422%
- Depreciation and Amortization 2.07 2.07
0% 0%
21%
EBIT (Operating Income) EBIT -144 -144
68% 68%
-1,443%
Net Profit -102 -102
68% 68%
-1,019%

In millions USD.

Don't miss a Thing! We will send you all news about Janux Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Janux Therapeutics Inc Stock News

Neutral
Business Wire
one day ago
SAN DIEGO--(BUSINESS WIRE)--Janux provided a program update on its Phase 1 study of JANX008, an EGFR-targeted TRACTr, following Phase 1a completion and cohort expansion.
Neutral
The Motley Fool
20 days ago
Meyer Andrew Hollman, Chief Business Officer at Janux Therapeutics (JANX 1.70%), exercised 16,665 options and immediately sold the resulting shares for a transaction value of approximately $501,000 on October 28, 2025, according to a recent SEC Form 4 filing.
Negative
Reuters
22 days ago
Shares of Janux Therapeutics slumped nearly 50% on Tuesday as investors reacted to limited disclosure in the company's early-stage study update for its prostate cancer treatment.
More Janux Therapeutics Inc News

Company Profile

Janux Therapeutics, Inc. operates preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded in June 2017 and is headquartered in La Jolla, CA.

Head office United States
CEO David Campbell
Employees 103
Founded 2017
Website www.januxrx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today